Digestive Remedies in Lithuania

Digestive Remedies in Lithuania

Rising prices are responsible for current value growth in digestive remedies in Lithuania in 2024, while volume sales are only marginal. Proton pump inhibitors are gaining share, which was lost by H2 blockers, with brands such as Nolpaza doing well in this situation. Nolpaza is praised for blocking the final step in the pathway of acid secretion in the stomach, while the former blocks only one of the first stimuli for acid production. In addition, Escadra, an esomeprazole-based medicine to fight...

Euromonitor International's Digestive Remedies in Lithuania report offers a comprehensive guide to the size and shape of the market at a national level. It provides the latest retail sales data 2019-2023, allowing you to identify the sectors driving growth. Forecasts to 2028 illustrate how the market is set to change.

Product coverage: Diarrhoeal Remedies, IBS Treatments, Indigestion and Heartburn Remedies, Laxatives, Motion Sickness Remedies, Paediatric Digestive Remedies.

Data coverage: market sizes (historic and forecasts), company shares, brand shares and distribution data.

Why buy this report?
* Get a detailed picture of the Digestive Remedies market;
* Pinpoint growth sectors and identify factors driving change;
* Understand the competitive environment, the market’s major players and leading brands;
* Use five-year forecasts to assess how the market is predicted to develop.